Special Issue "Antidepressants and Mood Stabilizers: Novel Research Avenues and Recent Evidence-Based Clinical Insights"
Deadline for manuscript submissions: closed (31 May 2018).
Prof. Dr. Domenico De Berardis
1. National Health Service, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital "G. Mazzini", ASL 4, Teramo, Italy
2. Chair of Psychiatry, University “G. d’Annunzio” of Chieti-Pescara, Italy
3. Polyedra Research Group, Italy
Website | E-Mail
Interests: clinical psychiatry; clinical psychopharmacology; clozapine; newer antidepressants; long-acting antipsychotics; alexithymia; emotions; functional somatic symptoms; anxiety disorders; mood disorders; schizophrenia; functional magnetic resonance; obsessive-compulsive disorder
Within the past few decades, the release of novel compounds occurred for the sole antidepressant class, rather than lithium or traditional anticonvulsant mood-stabilizers. Shifting of the boundary (and largely flawed) “class-effect” and the monoamine-modulation approach may have played a role on the latter scenario, especially in view of concurrent preliminary evidence suggesting a potential trans-nosological effect of selected second-generation antipsychotics, beyond only schizophrenia-spectrum disorders.
The present Special Issue aims at providing an overview on both the current and most promising novel avenues, of both standard antidepressant and “mood-stabilizer” agents in a broader sense, thus encompassing both boundary diagnostic systems, as well as alternative, evidence- and spectrum-based approaches, ideally driving a conscious prescription of pharmacological agents that are effective both in the treatment of major depressive episodes and the ideal longitudinal stabilization of bipolar disorder.
Prof. Dr. Domenico De Berardis
Dr. Michele Fornaro
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- mixed features/states
- second-generation antipsychotics
- experimental drugs